{"title":"Prediction of Survival Outcomes in Patients with Glioma Using Magnetic Resonance Imaging (MRI): A Systematic Review and Meta-Analysis.","authors":"Mingfang Hu, Jinge Li, Zhangyu Li, Jian Shen","doi":"10.31083/JIN23389","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Glioma is the most common malignancy in the central nervous system. Even with optimal therapies, glioblastoma (the most aggressive form of glioma) is incurable, with only 26.5% of patients having a 2-year survival rate. The present meta-analysis evaluated the association of magnetic resonance imaging (MRI)-derived parameters in glioma patients with progression-free survival (PFS) and overall survival. Eligible clinical articles on glioma patients included those that contained an evaluation of the association between MRI findings, PFS, and overall length of survival.</p><p><strong>Methods: </strong>Review of the literature included the following databases: WHO International Clinical Trials Registry Platform; Google Scholar; Web of Science; PubMed; SIGLE; NYAM; Scopus; Randomized controlled trial (RCT); Virtual Health Library (VHL); Cochrane Collaboration; EMBASE; and Clinical Trials.</p><p><strong>Results: </strong>The current review included 20 studies, and covered 2097 patients with gliomas. There were 1310 patients with glioblastoma and 320 with astrocytoma. There were 161 patients with grade-2 gliomas and 111 patients with grade-3. Tumour necrosis, peritumoural oedema, and multiple lesions were associated with PFS, as well as tumour necrosis and peritumoural oedema with overall survival.</p><p><strong>Conclusions: </strong>The present meta-analysis highlighted the ability of MRI to predict PFS and overall survival in patients with gliomas. This is crucial to identify patients at risk for poor survival outcomes and for individualising the treatment plan for such patients. The PROSPERO Registration: CRD42023489535, https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=489535.</p>","PeriodicalId":16160,"journal":{"name":"Journal of integrative neuroscience","volume":"24 1","pages":"23389"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of integrative neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31083/JIN23389","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Glioma is the most common malignancy in the central nervous system. Even with optimal therapies, glioblastoma (the most aggressive form of glioma) is incurable, with only 26.5% of patients having a 2-year survival rate. The present meta-analysis evaluated the association of magnetic resonance imaging (MRI)-derived parameters in glioma patients with progression-free survival (PFS) and overall survival. Eligible clinical articles on glioma patients included those that contained an evaluation of the association between MRI findings, PFS, and overall length of survival.
Methods: Review of the literature included the following databases: WHO International Clinical Trials Registry Platform; Google Scholar; Web of Science; PubMed; SIGLE; NYAM; Scopus; Randomized controlled trial (RCT); Virtual Health Library (VHL); Cochrane Collaboration; EMBASE; and Clinical Trials.
Results: The current review included 20 studies, and covered 2097 patients with gliomas. There were 1310 patients with glioblastoma and 320 with astrocytoma. There were 161 patients with grade-2 gliomas and 111 patients with grade-3. Tumour necrosis, peritumoural oedema, and multiple lesions were associated with PFS, as well as tumour necrosis and peritumoural oedema with overall survival.
Conclusions: The present meta-analysis highlighted the ability of MRI to predict PFS and overall survival in patients with gliomas. This is crucial to identify patients at risk for poor survival outcomes and for individualising the treatment plan for such patients. The PROSPERO Registration: CRD42023489535, https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=489535.
背景：神经胶质瘤是中枢神经系统最常见的恶性肿瘤。即使采用最佳的治疗方法，胶质母细胞瘤（最具侵袭性的胶质瘤）也是无法治愈的，只有26.5%的患者有2年的生存率。本荟萃分析评估了核磁共振成像（MRI）衍生参数与胶质瘤患者无进展生存期（PFS）和总生存期的关系。关于胶质瘤患者的合格临床文章包括那些包含MRI表现、PFS和总生存期之间关系的评估。方法：文献综述包括以下数据库：WHO国际临床试验注册平台；谷歌学者;Web of Science；PubMed;单身;NYAM;斯高帕斯;随机对照试验（RCT）；虚拟健康图书馆（VHL）；Cochrane协作;EMBASE;和临床试验。结果：目前的综述包括20项研究，涵盖了2097例胶质瘤患者。胶质母细胞瘤1310例，星形细胞瘤320例。2级胶质瘤161例，3级胶质瘤111例。肿瘤坏死、肿瘤周围水肿和多发病变与PFS相关，肿瘤坏死和肿瘤周围水肿与总生存率相关。结论：目前的荟萃分析强调了MRI预测胶质瘤患者PFS和总生存的能力。这对于识别存在生存风险的患者以及为此类患者制定个性化治疗方案至关重要。普洛斯彼罗注册：CRD42023489535， https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=489535。
期刊介绍：
JIN is an international peer-reviewed, open access journal. JIN publishes leading-edge research at the interface of theoretical and experimental neuroscience, focusing across hierarchical levels of brain organization to better understand how diverse functions are integrated. We encourage submissions from scientists of all specialties that relate to brain functioning.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
